Patents by Inventor Stefano Colloca

Stefano Colloca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11214599
    Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: January 4, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
  • Patent number: 11098324
    Abstract: The present invention relates to novel adenovirus strains with a high immunogenicity and no pre-existing immunity in the general human population. The lack of pre-existing immunity is due to novel hypervariable regions in the adenoviral capsid protein hexon. The novel adenovirus strains also have an improved capacity for reproduction. The present invention provides nucleotide and amino acid sequences of these novel adenovirus strains, as well as recombinant viruses, virus-like particles and vectors based on these strains. Further provided are pharmaceutical compositions and medical uses in the therapy or prophylaxis of a disease, and methods for producing an adenovirus or virus-like particles utilizing the novel sequences, recombinant viruses, virus-like particles and vectors.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: August 24, 2021
    Assignee: Nouscom AG
    Inventors: Alfredo Nicosia, Stefano Colloca, Armin Lahm
  • Publication number: 20210246468
    Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
    Type: Application
    Filed: June 11, 2019
    Publication date: August 12, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Stefania CAPONE, Stefano COLLOCA, Antonella FOLGORI, Rosella MERONE
  • Publication number: 20210189420
    Abstract: A new promoter comprising: (i) an hCMV enhancer sequence; (ii) an hCMV promoter sequence; (iii) a splice donor region; (iv) a cell-derived enhancer sequence; and (v) a splice acceptor region.
    Type: Application
    Filed: October 16, 2018
    Publication date: June 24, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Stefano COLLOCA
  • Publication number: 20210189421
    Abstract: Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.
    Type: Application
    Filed: October 16, 2018
    Publication date: June 24, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia AMMENDOLA, Stefano COLLOCA, Alessandra VITELLI
  • Publication number: 20210189422
    Abstract: An adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein each transgene encodes an RSV antigenic protein or a fragment thereof.
    Type: Application
    Filed: October 16, 2018
    Publication date: June 24, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Stefano COLLOCA
  • Publication number: 20210130848
    Abstract: The present invention relates to novel adenovirus strains with a high immunogenicity and no pre-existing immunity in the general human population. The lack of pre-existing immunity is due to novel hypervariable regions in the adenoviral capsid protein hexon. The novel adenovirus strains also have an improved capacity for reproduction. The present invention provides nucleotide and amino acid sequences of these novel adenovirus strains, as well as recombinant viruses, virus-like particles and vectors based on these strains. Further provided are pharmaceutical compositions and medical uses in the therapy or prophylaxis of a disease, and methods for producing an adenovirus or virus-like particles utilizing the novel sequences, recombinant viruses, virus-like particles and vectors.
    Type: Application
    Filed: July 5, 2018
    Publication date: May 6, 2021
    Inventors: Alfredo NICOSIA, Stefano COLLOCA, Armin LAHM
  • Publication number: 20210060150
    Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.
    Type: Application
    Filed: August 6, 2020
    Publication date: March 4, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra VITELLI, Alfredo NICOSIA, Riccardo CORTESE
  • Publication number: 20200308601
    Abstract: The present invention relates to a cell line, use of the cell line and a method for producing infectious viral particles using said cell line.
    Type: Application
    Filed: October 25, 2018
    Publication date: October 1, 2020
    Inventors: Stefano COLLOCA, Alfredo NICOSIA
  • Publication number: 20200299651
    Abstract: A simian adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein the first expression cassette is inserted in the E1 region of the simian adenoviral vector, and the second expression cassette is inserted in a region of the adenoviral vector that is compatible with vector replication.
    Type: Application
    Filed: October 16, 2018
    Publication date: September 24, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Stefano COLLOCA
  • Publication number: 20200164061
    Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
    Type: Application
    Filed: February 5, 2020
    Publication date: May 28, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano COLLOCA, Riccardo CORTESE, Antonella FOLGORI, Alfredo NICOSIA
  • Publication number: 20200149069
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Application
    Filed: January 24, 2020
    Publication date: May 14, 2020
    Applicants: The Government of the United States of America as Represented by the Secretary of the Department of, GlaxoSmithKline Biologicals SA
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Publication number: 20200140886
    Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.
    Type: Application
    Filed: June 10, 2016
    Publication date: May 7, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Virginia AMMENDOLA, Stefano COLLOCA, Riccardo CORTESE, Fabiana GRAZIOLI, Alfredo NICOSIA, Alessandra VITELLI
  • Publication number: 20200102352
    Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 2, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
  • Patent number: 10588961
    Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
  • Patent number: 10584355
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 10, 2020
    Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 10576143
    Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 3, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
  • Patent number: 10544192
    Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 28, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Sr., Virginia Ammendola, Maria Ambrosio
  • Publication number: 20190300905
    Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
    Type: Application
    Filed: December 7, 2017
    Publication date: October 3, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Virginia AMMENDOLA, Stefania CAPONE, Stefano COLLOCA, Antonella FOLGORI, Rosella MERONE
  • Publication number: 20180216081
    Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.
    Type: Application
    Filed: July 25, 2016
    Publication date: August 2, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra VITELLI, Alfredo NICOSIA, Riccardo CORTESE